Study summary · research use only
Tesamorelin
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This is a drug-information summary (human; general clinical description, not an original clinical trial) about tesamorelin, a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in HIV-infected patients with lipodystrophy. The abstract reports that tesamorelin is given subcutaneously and has major effects on glucose and lipid metabolism, but has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury.
Abstract
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipid metabolism, but has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.